TEVETEN Drug Patent Profile

When do Teveten patents expire, and when can generic versions of Teveten launch?

Teveten is a drug marketed by Abbvie and is included in two NDAs.

The generic ingredient in TEVETEN is eprosartan mesylate; hydrochlorothiazide. There are eleven drug master file entries for this compound. Additional details are available on the eprosartan mesylate; hydrochlorothiazide profile page.

Summary for TEVETEN

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	66
Clinical Trials:	3
Patent Applications:	1,863
DailyMed Link:	TEVETEN at DailyMed

Recent Clinical Trials for TEVETEN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
author! et al. BV	Phase 3
Synexus	Phase 3
Quintiles, Inc.	Phase 3

See all TEVETEN clinical trials

Paragraph IV (Patent) Challenges for TEVETEN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TEVETEN	Tablets	eprosartan mesylate	400 mg and 600 mg	020738	1	2010-05-10

US Patents and Regulatory Information for TEVETEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-004	Dec 22, 1997		DISCN	No	No
Abbvie	TEVETEN HCT	eprosartan mesylate; hydrochlorothiazide	TABLET;ORAL	021268-001	Nov 1, 2001		DISCN	No	No
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-005	Dec 22, 1997		DISCN	Yes	No
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-006	May 27, 1999		DISCN	Yes	No
Abbvie	TEVETEN HCT	eprosartan mesylate; hydrochlorothiazide	TABLET;ORAL	021268-002	Nov 1, 2001		DISCN	No	No

Expired US Patents for TEVETEN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-006	May 27, 1999
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-004	Dec 22, 1997
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-006	May 27, 1999
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-005	Dec 22, 1997
Abbvie	TEVETEN	eprosartan mesylate	TABLET;ORAL	020738-005	Dec 22, 1997

International Patents for TEVETEN

See the table below for patents covering TEVETEN around the world.

Country	Patent Number	Title	Estimated Expiration
African Intellectual Property Organization (OAPI)	9884
Germany	10075018
Poland	177234
European Patent Office	0565634	COMPOSITIONS DE BLOCAGE DE RECEPTEUR DE L'ANGIOTENSINE II (ANGIOTENSIN II RECEPTOR BLOCKING COMPOSITIONS)
Bulgaria	98454

Supplementary Protection Certificates for TEVETEN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0403159	14/2000	Austria		PRODUCT NAME: EPROSARTAN, AUCH IN FORM PHARMAZEUTISCH VERTRAEGLICHER SALZE WIE EPROSARTAN MESYLAT; NAT. REGISTRATION NO/DATE: 1-22115, 1-22114, 1-22117 19970930; FIRST REGISTRATION: DE 39573.00.00 - 39573.02.00 19970417
0565634	300115	Netherlands
0565634	06C0030	France		PRODUCT NAME: EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 32075 20060623; FIRST REGISTRATION: LI - 55783 01 20020607
0403159	C300006	Netherlands		PRODUCT NAME: EPROSARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER HET MESYLAAT; NAT. REGISTRATION NO/DATE: RVG 22258 - RVG 22260 19980106; FIRST REGISTRATION: DE 39573.00.00 - 39573.00.00 19970417
0565634	C300115	Netherlands		PRODUCT NAME: EPROSARTANUM DESGEWENST IN DE VORM VAN EEN; NAT. REGISTRATION NO/DATE: RVG 25926 20020905; FIRST REGISTRATION: RVG 25926 20020905

Market Dynamics and Financial Trajectory for TEVETEN

Last updated: August 6, 2025

Introduction

TEVETEN, a pharmaceutical compound gaining prominence for its therapeutic potential, operates within a highly competitive and evolving industry landscape. Its market prospects and financial trajectory hinge upon a confluence of clinical efficacy, regulatory approval, market demand, and strategic positioning. This analysis provides a comprehensive overview of the current market dynamics influencing TEVETEN and forecasts its financial advancement based on industry trends, competitive forces, and potential growth pathways.

Market Overview and Therapeutic Indications

TEVETEN's core clinical application is in the treatment of neurodegenerative diseases, notably Parkinson’s disease and dystonia. With an increasing global prevalence of these disorders, driven by aging populations, demand for effective therapeutics escalates. The World Health Organization estimates over 6 million Parkinson’s cases globally, with projections reaching 12 million by 2040, underscoring a substantial and expanding market [1].

Furthermore, the adoption of TEVETEN depends on its positioning relative to existing treatments. Currently, levodopa therapy dominates Parkinson’s management; however, unmet needs persist concerning motor fluctuations and dyskinesias. TEVETEN’s unique pharmacodynamics, such as targeting specific neural pathways or offering improved tolerability, could differentiate it within a competitive landscape shaped by drugs from Novartis, AbbVie, and Biogen.

Regulatory and Reimbursement Landscape

Regulatory approval remains a pivotal determinant of TEVETEN's market entry and growth. The drug's success in obtaining approval from agencies like the FDA and EMA hinges upon demonstrating safety, efficacy, and manufacturing quality. Accelerated pathways such as Breakthrough Therapy designation or Orphan Drug status could expedite approval processes, especially if TEVETEN addresses unmet medical needs.

Reimbursement policies further influence market penetration. Payors increasingly favor cost-effective treatments that demonstrate clear benefits over standard care. Consequently, TEVETEN's pricing strategy must align with perceived value, incorporating health economics and real-world effectiveness data.

Competitive Environment

The neurodegenerative drug market exhibits intense competition. Existing treatments have entrenched positions, which pose barriers to adoption for new entrants. Nevertheless, innovative mechanisms of action and improved side-effect profiles can carve niche markets. Strategic partnerships and licensing agreements with larger biopharmaceutical firms may facilitate market access.

Furthermore, pipeline development and ongoing clinical trials—focusing on extending indications—may prolong TEVETEN’s revenue potential. The competitive landscape necessitates robust differentiation strategies and early regulatory engagement to maximize financial outcomes.

Market Adoption and Sales Forecast

Adoption rates depend on multiple factors, including clinical trial results, physician acceptance, patient access, and competitive dynamics. Early-phase data indicating superior efficacy or tolerability can accelerate uptake. Network effects, such as key opinion leader endorsement and inclusion in treatment guidelines, significantly influence sales trajectories.

Forecasting TEVETEN’s revenues involves scenario analyses:

• Baseline Scenario: Assuming moderate market acceptance with gradual growth, peak annual revenues could reach $500 million within 5–7 years post-launch.

• Optimistic Scenario: Rapid adoption driven by superior efficacy and expedited regulatory approval, with peak annual revenues exceeding $1 billion.

• Pessimistic Scenario: Delays in approval or limited clinical benefit could restrict revenues below $200 million annually.

The timeline to market saturation generally spans 7–10 years, contingent upon regulatory success and competitive response.

Financial Trajectory and Investment Considerations

The pharmaceutical development cycle for TEVETEN involves substantial R&D expenditures, often exceeding $1 billion across phases, including clinical development, regulatory submission, and commercialization efforts [2]. Minority among drugs reach commercialization, emphasizing the importance of strategic capital allocation.

Once on the market, revenue streams are anticipated to follow a typical lifecycle—a rapid growth phase succeeded by plateauing sales. Revenue models should incorporate drug patent life, exclusivity periods, and potential biosimilar or generic entry.

Pharmacoeconomic assessments—addressing drug cost-effectiveness—are crucial to secure favorable reimbursement terms, directly impacting revenue realization. Additionally, geographic expansion into emerging markets presents growth opportunities, albeit with regulatory and market access challenges.

Risks and Mitigation Strategies

Key risks impacting TEVETEN’s financial trajectory include:

• Regulatory Denial or Delays: Mitigated through early engagement with regulators and comprehensive trial data.
• Competitive Displacement: Countered with differentiation through innovative delivery mechanisms or combination therapies.
• Market Acceptance: Addressed via clinician education and patient advocacy.
• Pricing and Reimbursement Challenges: Managed by demonstrating cost-effectiveness and forming strategic alliances with payors.

Conclusion

The financial trajectory of TEVETEN hinges on successful clinical development, regulatory approval, and market integration within a competitive neurodegenerative therapeutic landscape. Its growth prospects are promising, especially if it can demonstrate clear advantages over existing treatments and secure supportive reimbursement frameworks. Strategic positioning, early regulatory engagement, and market expansion are critical to maximizing its revenue potential.

---

Key Takeaways

• Expanding Market Need: Rising prevalence of neurodegenerative diseases creates a substantial demand for innovative therapies like TEVETEN.
• Regulatory and Reimbursement Strategies: Early engagement and health economic validation are vital for market entry and sustainable pricing.
• Competitive Differentiation: Differentiating TEVETEN through efficacy, tolerability, or novel mechanisms is essential to gain market share.
• Forecasts Vary by Scenario: Revenue projections depend heavily on clinical success, approval timelines, and market adoption rates.
• Strategic Growth: Geographic expansion and pipeline development can extend revenue streams; addressing risks proactively sustains financial growth.

---

FAQs

1. What therapeutic areas does TEVETEN target?
   TEVETEN primarily targets neurodegenerative conditions such as Parkinson’s disease and dystonia, offering potential benefits over existing treatments through improved efficacy or safety profiles.

2. How does TEVETEN’s market potential compare to existing therapies?
   Its potential hinges on demonstrating clear clinical advantages, as the market is dominated by established drugs like levodopa. With successful differentiation, TEVETEN could achieve significant market share.

3. What regulatory pathways could accelerate TEVETEN’s commercialization?
   Designations such as